EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

other/Company Information/molecular diagnostics
21.12.2012

Not for distribution in the United States

Berlin, Germany, December 21, 2012 - The Executive Board of
Epigenomics AG (ISIN: E000A1K0516) notifies that during the
preparation of the annual financial statements pursuant to German
GAAP (HGB) accounting, according to its best judgment a cumulative
loss of more than half of the nominal share capital of the company
has been incurred. This is mainly attributable to budgeted losses
from regular business operations but as well to higher than expected
expenses in connection with the recently completed clinical study.

The Executive Board is actively reviewing different measures to
compensate for the loss of half of the nominal share capital. The
planned rights issue in January 2013 as announced previously on
December 20, 2012 is part of the measures, which aim at improving the
Company's equity and liquidity.

Pursuant to Sec. 92 par. 1 German Stock Corporation Act
("Aktiengesetz"), a loss amounting to half of the nominal share
capital triggers the statutory obligation to summon a general meeting
of shareholders without undue delay. The Executive Board will
therefore invite to an extraordinary general meeting in due course.
In this meeting, the Executive Board will notify the loss of half of
the nominal share capital and outline the situation of the company.
An invitation including an agenda to the extraordinary general
meeting will be provided in due time and form.

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG
and its business. Such statements involve certain known and unknown
risks, uncertainties and other factors which could cause the actual
results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English